

Anja Strangfeld

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5378834/publications.pdf>

Version: 2024-02-01

56
papers

6,972
citations

185998

28
h-index

138251

58
g-index

63
all docs

63
docs citations

63
times ranked

7584
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.5	1,860
2	Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 859-866.	0.5	908
3	Infections in patients with rheumatoid arthritis treated with biologic agents. <i>Arthritis and Rheumatism</i> , 2005, 52, 3403-3412.	6.7	620
4	Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 930-942.	0.5	496
5	Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti-TNF Agents. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 737.	3.8	485
6	Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. <i>Arthritis Research and Therapy</i> , 2010, 12, R5.	1.6	224
7	Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNF inhibitors and rituximab. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 415-421.	0.5	217
8	Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: Comparison of patients according to their eligibility for major randomized clinical trials. <i>Arthritis and Rheumatism</i> , 2006, 54, 3399-3407.	6.7	210
9	Does tumor necrosis factor inhibition promote or prevent heart failure in patients with rheumatoid arthritis?. <i>Arthritis and Rheumatism</i> , 2008, 58, 667-677.	6.7	191
10	Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. <i>Lancet Rheumatology</i> , The, 2020, 2, e250-e253.	2.2	172
11	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1137-1146.	0.5	151
12	Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 386-391.	0.5	150
13	Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 695-709.	0.5	130
14	Response to: Correspondence on Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry by Mulhearn et al. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e116-e116.	0.5	87
15	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2129639.	2.8	86
16	Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. <i>RMD Open</i> , 2021, 7, e001464.	1.8	82
17	Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 2025-2030.	0.5	77
18	Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT. <i>Rheumatology</i> , 2015, 54, 1858-1866.	0.9	56

#	ARTICLE	IF	CITATIONS
19	Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 183.	1.6	51
20	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 970-978.	0.5	49
21	Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the "JAK-pot"™ collaboration. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1358-1366.	0.5	48
22	National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD. <i>RMD Open</i> , 2020, 6, e001332.	1.8	44
23	Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 41-47.	0.5	39
24	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. <i>Lancet Rheumatology, The</i> , 2021, 3, e855-e864.	2.2	38
25	Body mass index distribution in rheumatoid arthritis: a collaborative analysis from three large German rheumatoid arthritis databases. <i>Arthritis Research and Therapy</i> , 2016, 18, 149.	1.6	36
26	EULAR recommendations for a core data set for pregnancy registries in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 49-56.	0.5	36
27	How well do patient reports reflect adverse drug reactions reported by rheumatologists? Agreement of physician- and patient-reported adverse events in patients with rheumatoid arthritis observed in the German biologics register. <i>Rheumatology</i> , 2011, 50, 152-160.	0.9	35
28	2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1160-1166.	0.5	34
29	SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. <i>RMD Open</i> , 2022, 8, e002187.	1.8	34
30	SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 145-150.	0.5	30
31	Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis. <i>Rheumatology</i> , 2020, 59, 1916-1926.	0.9	24
32	TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. <i>RMD Open</i> , 2021, 7, e001896.	1.8	22
33	Sustainability of Rituximab Therapy in Different Treatment Strategies: Results of a 3-Year Followup of a German Biologics Register. <i>Arthritis Care and Research</i> , 2014, 66, 1627-1633.	1.5	21
34	Are prognostic factors adequately selected to guide treatment decisions in patients with rheumatoid arthritis? A collaborative analysis from three observational cohorts. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 976-982.	1.6	20
35	European Network of Pregnancy Registers in Rheumatology (EuNeP) – an overview of procedures and data collection. <i>Arthritis Research and Therapy</i> , 2019, 21, 241.	1.6	19
36	Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers. <i>Rheumatology</i> , 2011, 50, 146-151.	0.9	18

#	ARTICLE	IF	CITATIONS
37	Factors associated with treatment satisfaction in patients with rheumatoid arthritis: data from the biological register RABBIT. RMD Open, 2020, 6, e001290.	1.8	18
38	Rheumatoid arthritis treatment in patients with a history of cancer. Current Opinion in Rheumatology, 2018, 30, 288-294.	2.0	15
39	Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort. Rheumatology International, 2018, 38, 579-587.	1.5	13
40	Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic, including recommendations for COVID-19 vaccination. Zeitschrift Fur Rheumatologie, 2021, 80, 33-48.	0.5	13
41	EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology. Annals of the Rheumatic Diseases, 2022, 81, 780-785.	0.5	12
42	Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases. Annals of the Rheumatic Diseases, 2022, 81, 998-1005.	0.5	12
43	Pregnancy in women with psoriatic arthritis: A systematic literature review of disease activity and adverse pregnancy outcomes. Seminars in Arthritis and Rheumatism, 2021, 51, 530-538.	1.6	11
44	COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. Journal of Rheumatology, 2022, 49, 110-114.	1.0	9
45	Primary and secondary patient data in contrast: the use of observational studies like RABBIT. Clinical and Experimental Rheumatology, 2016, 34, S79-S86.	0.4	8
46	EULAR COVID-19 registry: lessons learnt and future considerations. Annals of the Rheumatic Diseases, 2021, 80, 1110-1115.	0.5	6
47	TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. RMD Open, 2021, 7, .	1.8	6
48	Incidence of facial nerve palsies stratified by DMARD treatment in patients with rheumatoid arthritis: data from the RABBIT register. RMD Open, 2020, 6, e001403.	1.8	5
49	Maternal and infant outcomes in pregnancies of women with axial spondyloarthritis compared with matched controls: results from nationwide health insurance data. RMD Open, 2022, 8, e002146.	1.8	5
50	Methotrexate: what are the true risks of treatment?. Annals of the Rheumatic Diseases, 2020, 79, 1267-1268.	0.5	4
51	Response to: "Correspondence on "EULAR recommendations for a core data set for pregnancy registries in rheumatology" by De Cock et al". Annals of the Rheumatic Diseases, 2023, 82, e45-e45.	0.5	4
52	Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology. RMD Open, 2021, 7, e001818.	1.8	4
53	Mobile Responsive App "A Useful Additional Tool for Data Collection in the German Pregnancy Register Rhekiss?". Frontiers in Medicine, 2021, 8, 773836.	1.2	3
54	OP0226...SOLID TUMOUR OUTCOMES IN PATIENTS WITH RA TREATED WITH ABATACEPT AND OTHER DMARDS: RESULTS FROM A 10-YEAR INTERNATIONAL POST-APPROVAL STUDY., 2019, , .		2

#	ARTICLE	IF	CITATIONS
55	Response to: "Correspondence on "Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry" by Arnaud and Devilliers. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e114-e114.	0.5	2
56	Response to: "Correspondence on "Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry" by Rosenbaum et al. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e139-e139.	0.5	2